Spondyloarthritis & psoriatic arthritis
Flare prediction after tapering the dose of tumour necrosis factor inhibitors in patients with axial spondyloarthritis: a nationwide cohort study
Authors' conclusion
The established prediction model accurately predicted the risk of flares after TNFi dose tapering in patients with axSpA using eight simple clinical parameters
Study context
- Population
- Patients with axial spondyloarthritis (axSpA) who received standard-dose tumour necrosis factor inhibitors (TNFi) for at least 1 year and tapered their dose; Korean College of Rheumatology Biologics and Targeted Therapy Registryderivation cohort
- Participants
- 526 patients
- Comparison
- Low-risk vs Intermediate-risk vs High-risk
- Outcome
- Flare: Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) ≥2.1 after 1 year of TNFi tapering
- Follow-up
- 1 year after tapering
Methodological detailsnationwide, registry-based, independent validation cohort
- Nationwide
- Registry-based
- Independent validation cohort
Performance
As reported in the abstract
Flare (ASDAS-CRP ≥2.1) after 1 year of TNFi tapering
Flares, all patients (127/526)
24.1%
Model discrimination, AUC
0.828
Further findings
Model performance in independent validation cohort
- Performance comparable
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Flare prediction after tapering the dose of tumour necrosis factor inhibitors in patients with axial spondyloarthritis: a nationwide cohort study. Rheumatology (Oxford). Published 13 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →